AbbVie (ABBV) Free Cash Flow (QoQ) (2012 - 2026)
AbbVie (ABBV) Free Cash Flow (QoQ) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.10% |
| Dec 31, 2025 | -26.40% |
| Sep 30, 2025 | 36.02% |
| Jun 30, 2025 | 248.86% |
| Mar 31, 2025 | -79.28% |
| Dec 31, 2024 | 29.99% |
| Sep 30, 2024 | 156.06% |
| Jun 30, 2024 | -47.23% |
| Mar 31, 2024 | -15.41% |
| Dec 31, 2023 | -38.16% |
| Sep 30, 2023 | 19.77% |
| Jun 30, 2023 | 52.84% |
| Mar 31, 2023 | -44.31% |
| Dec 31, 2022 | -2.83% |
| Sep 30, 2022 | 52.71% |
| Jun 30, 2022 | 2.44% |
| Mar 31, 2022 | -2.91% |
| Dec 31, 2021 | -36.67% |
| Sep 30, 2021 | 64.39% |
| Jun 30, 2021 | 0.13% |